Bladder-preserving trimodality therapy with capecitabine
Connor Lynch,Randy F. Sweis,Parth Modi,Piyush K. Agarwal,Russell Z. Szmulewitz,Walter M. Stadler,Peter H. O'Donnell,Stanley L. Liauw,Sean P. Pitroda
DOI: https://doi.org/10.1016/j.clgc.2024.01.002
IF: 3.121
2024-01-10
Clinical Genitourinary Cancer
Abstract:Introduction/Background Many patients with muscle-invasive bladder cancer are poor candidates for radical cystectomy or trimodality therapy (TMT) with maximal trans-urethral resection of bladder tumor (TURBT) and chemoradiotherapy (cRT) with cisplatin or mitomycin C. Given the benefit of chemotherapy in bladder-preserving therapy, less-intense concurrent chemotherapy regimens are needed. This study reports on efficacy and toxicity for patients treated with TMT using single-agent concurrent capecitabine. Materials and Methods Patients deemed ineligible for radical cystectomy or standard cRT by a multidisciplinary tumor board and patients who refused cystectomy were included. Following TURBT, patients received twice-daily capecitabine (goal dose 825 mg/m 2 ) concurrent with radiotherapy to the bladder +/- pelvis depending on nodal staging and patient risk factors. Toxicity was evaluated prospectively in weekly on-treatment visits and follow-up visits by the treating physicians. Descriptive statistics are provided. Overall (OS), progression-free (PFS), cancer-specific (CSS), distant metastasis-free (DMFS), and bladder recurrence-free survival (BRFS) were estimated using the Kaplan-Meier method. Results Twenty-seven consecutive patients met criteria for inclusion from 2013 to 2023. The median age was 79 with nine patients staged cT3-4a and seven staged cN1-3. The rate of complete response in the bladder and pelvis was 93%. OS, PFS, CSS, DMFS, and BRFS at 2 years were estimated as 81%, 65%, 91%, 75%, and 92%, respectively. There were two bladder recurrences, both non-invasive. There were seven grade 3 acute hematologic or metabolic events but no other grade 3+ toxicities. Conclusion Maximal TURBT followed by radiotherapy with concurrent capecitabine offers a high rate of bladder control and low rates of acute and late toxicity. Micro While combined chemoradiotherapy is superior to radiotherapy alone bladder-preserving therapy in patients with bladder cancer, standard chemoradiotherapy regimens are prohibitively toxic for certain patients. We present results from our institutional experience treating patients with oral capecitabine concurrent with radiotherapy following trans-urethral resection of bladder tumor. Importantly, no patients required salvage cystectomy and overall toxicity was low.
oncology,urology & nephrology